释放对后审批变更的依赖的力量:与48个国家监管机构一起的旅程
Francesca Mangia1, Yameng Melly Lin2, John Armando3
1F.Hoffmann-La Roche, Grenzacherstrasse 124, Basel, 4058, Switzerland. francesca.mangia@roche.com.
Therapeutic innovation & regulatory science
|July 24, 2024
概括
一个使用监管依赖于批准后变更 (PAC) 的试点项目旨在加快全球药物批准并确保持续的药物供应. 这一举措简化了关键制造变更的审查过程,使全球患者受益.
科学领域:
- 制药制造业和监管事务
- 全球卫生政策和药物监管
背景情况:
- 批准后的变化 (PAC) 对于产品生命周期管理至关重要,但面临着漫长的全球监管审查,影响药品供应连续性.
- 世界卫生组织 (WHO) 支持的依赖途径在PAC中未得到充分利用,尽管在最初的营销许可中取得了成功.
研究的目的:
- 通过监管依赖试点,加快对单克隆抗体供应关键变异的审查和批准.
- 通过在6.5个月内获得全球批准的目标,确保关键药物的持续供应.
- 通过利用欧洲药品管理局 (EMA) 的批准,促进国家监管机构 (NRA) 之间的监管趋同和透明度.
主要方法:
- 建立了一个依赖试点,利用EMA的批准,将主要的化学,制造和控制 (CMC) 改变为单克隆抗体制造工艺.
- 一个与欧盟提交相同的标准化变化包,被提供给所有参与的NRA.
- 在规划和实施阶段,与EMA,世卫组织和48个参与的NRA进行了接触.
主要成果:
- 该试点成功吸引了48个国家监管机构 (NRA) 加入关键药物变异的依赖途径.
- 该倡议旨在简化全球批准时间表,为6.5个月.
- 该过程通过放弃国家特定要求来促进监管融合,并通过共享评估报告提高透明度.
结论:
- 监管依赖提供了一个可行的策略,以加快关键药物的批准后变化,确保供应连续性.
- 监管机构和制药公司之间的合作努力可以促进全球监管趋同.
- 该试点展示了一个成功的模型,利用已有的监管批准来加速全球获得基本治疗的机会.
相关概念视频
Drug Regulation
1.3K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
1.3K
Pharmacovigilance
810
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
810
Drug Control Governance: Regulatory Bodies and Their Impact
149
Drug control governance involves the oversight and regulation of pharmaceuticals to ensure their safety and efficacy while preventing illegal drug use and trafficking. Regulatory bodies, including the US Food and Drug Administration (FDA) and the European Union's European Medicines Agency (EMA), play a central role in this process. These agencies evaluate the safety and efficacy of drugs before they can be marketed. They fund clinical trials and assess the benefits and risks associated with...
149
Clinical Trials: Overview
2.9K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.9K
Drug Nomenclature
1.7K
During the development of a new pharmaceutical, the manufacturer initially assigns a code name to the drug. Once approved, the drug receives a United States Adopted Name (USAN)—a generic, nonproprietary designation. Upon being listed in the United States Pharmacopeia, this nonproprietary name becomes the drug's official name. Additionally, the manufacturer assigns a proprietary name or trademark, which serves as the brand name under which the drug is marketed. It is worth noting that...
1.7K
Preclinical Development: Overview
4.4K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.4K


